At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Apr 17, 2026 at 15:00 ET
Immatics announced a deep and ongoing remission in a 17-year-old pediatric patient with advanced nephroblastoma after treatment with its PRAME-directed TCR T-cell therapy (IMA203CD8) under a named-patient use program. The case, to be presented at AACR 2026, demonstrates strong anti-tumor activity across multiple metastatic sites and supports the potential of PRAME-targeted cell therapy in pediatric solid tumors.
- 17-year-old pediatric patient with PRAME-positive nephroblastoma achieved deep remission after treatment with Immatics' IMA203CD8 TCR T-cell therapy.
- Remission included marked regression of liver, lung, and brain metastases, ongoing at 6 months post-infusion.
- Molecular remission confirmed via liquid biopsy with no detectable tumor-derived DNA.
- Safety events included manageable cytokine release syndrome resolved with standard therapy.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access